Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia

Anemia represents a common side effect of cancer chemotherapy, and results in diminished overall well-being as well as side effects such as dyspnea, f atigue and decreased appetite. Treatment options for chemotherapy-induced a nemia are transfusion of red blood cells and s.c. erythropoietin. Although transfusion is generally well tolerated, patients usually experience fluctu ating hemoglobin levels because of hesitancy to transfuse to normal hemoglo bin levels. Additionally, concerns persist related to the safety of blood p roducts, including the transmission of blood-borne pathogens, immunomodulat ion by transfusion and severe allergic reactions, despite advances in trans fusion medicine. Erythropoietin is an effective alternative to transfusion in many patients and allows for a more consistent hemoglobin level. The cos ts associated with the drug have limited its use. In addition, patient pref erences for the two treatment options have not been investigated. Economic analyses, including consideration of the costs associated with medical care as well as the consequences, will be essential in evaluating the potential of transfusions and erythropoietin in treating the anemia associated with cancer chemotherapy. [(C) 1998 Lippincott Williams & Wilkins.].